Literature DB >> 32016606

Microglia and Parkinson's disease: footprints to pathology.

Ekaterina Lazdon1, Nofar Stolero1, Dan Frenkel2,3.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disease associated with motor deficiency and rigidity. The genetic risks of the disease is reported to be between 5 and 10% depending on the background of the population. While PD is not considered an immune-mediated disease, amounting evidence in recent years suggests a major role of inflammation in the progression of PD. Markers of inflammation can be found around the regions of risk and adjacent to the appearance of Lewy bodies within the basal ganglia and the substantia nigra (SN) that are associated with PD pathology. Microglia, an important type of brain cell, has been reported to play a major role in mediating neuroinflammation and in PD disease pathology. This review aims to point out the potential role of microglia in disease progression and suggest that the interaction of microglia with the dopaminergic neurons may also facilitate the specificity of the disease in brain regions affected by PD.

Entities:  

Keywords:  Inflammation; Microglia; Neurotoxicity; Parkinson’s disease; Therapy

Year:  2020        PMID: 32016606     DOI: 10.1007/s00702-020-02154-6

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  8 in total

Review 1.  Alpha-Synuclein and LRRK2 in Synaptic Autophagy: Linking Early Dysfunction to Late-Stage Pathology in Parkinson's Disease.

Authors:  Giulia Lamonaca; Mattia Volta
Journal:  Cells       Date:  2020-04-30       Impact factor: 6.600

2.  Astrogliosis and sexually dimorphic neurodegeneration and microgliosis in the olfactory bulb in Parkinson's disease.

Authors:  Alicia Flores-Cuadrado; Daniel Saiz-Sanchez; Alicia Mohedano-Moriano; Elena Lamas-Cenjor; Victor Leon-Olmo; Alino Martinez-Marcos; Isabel Ubeda-Bañon
Journal:  NPJ Parkinsons Dis       Date:  2021-01-21

3.  Velvet Antler Methanol Extracts Ameliorate Parkinson's Disease by Inhibiting Oxidative Stress and Neuroinflammation: From C. elegans to Mice.

Authors:  Ying Liu; Hongyuan Li; Yunfei Li; Min Yang; Xiaohui Wang; Yinghua Peng
Journal:  Oxid Med Cell Longev       Date:  2021-01-08       Impact factor: 6.543

Review 4.  Modulation of microglia activation and Alzheimer's disease: CX3 chemokine ligand 1/CX3CR and P2X7R signaling.

Authors:  Pavithra Suresh; Sarayut Phasuk; Ingrid Y Liu
Journal:  Tzu Chi Med J       Date:  2021-01-05

Review 5.  Targeting α-Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models.

Authors:  Angeliki Spathopoulou; Frank Edenhofer; Lisa Fellner
Journal:  Front Neurol       Date:  2022-01-25       Impact factor: 4.003

6.  Altered expression of the immunoregulatory ligand-receptor pair CD200-CD200R1 in the brain of Parkinson's disease patients.

Authors:  Neus Rabaneda-Lombarte; José Manuel Vidal-Taboada; Tony Valente; Mario Ezquerra; Rubén Fernández-Santiago; María José Martí; Yaroslau Compta; Josep Saura; Carme Solà
Journal:  NPJ Parkinsons Dis       Date:  2022-03-16

7.  Dysregulation of Human Somatic piRNA Expression in Parkinson's Disease Subtypes and Stages.

Authors:  Tianjiao Zhang; Garry Wong
Journal:  Int J Mol Sci       Date:  2022-02-23       Impact factor: 5.923

8.  Cathepsin L-containing exosomes from α-synuclein-activated microglia induce neurotoxicity through the P2X7 receptor.

Authors:  Tianfang Jiang; Chuanying Xu; Shane Gao; Jia Zhang; Jia Zheng; Xiaolin Wu; Qiuyun Lu; Limei Cao; Danjing Yang; Jun Xu; Xu Chen
Journal:  NPJ Parkinsons Dis       Date:  2022-10-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.